#1l search results

اللهم ارحم والدينا واغفر لهما واجمعنا بهم في الفردوس الأعلى #أدعية_إسلامية [V@#1L@p2NP]


Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do) @OncoAlert #GI26

jgong15's tweet image. Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do)

@OncoAlert #GI26
jgong15's tweet image. Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do)

@OncoAlert #GI26
jgong15's tweet image. Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do)

@OncoAlert #GI26
jgong15's tweet image. Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do)

@OncoAlert #GI26

Dr. Kato post-hoc analysis of RATIONALE-305 trial of #1L chemo +/- tisle in adv #GC/GEJC ➡️ higher baseline ECOG-PS sig associated w/lower PROs but not with GC-specific domains, suggesting that ECOG-PS may not reflect GC-specific symptom burden at baseline @OncoAlert #GI26

jgong15's tweet image. Dr. Kato post-hoc analysis of RATIONALE-305 trial of #1L chemo +/- tisle in adv #GC/GEJC ➡️ higher baseline ECOG-PS sig associated w/lower PROs but not with GC-specific domains, suggesting that ECOG-PS may not reflect GC-specific symptom burden at baseline 

@OncoAlert #GI26
jgong15's tweet image. Dr. Kato post-hoc analysis of RATIONALE-305 trial of #1L chemo +/- tisle in adv #GC/GEJC ➡️ higher baseline ECOG-PS sig associated w/lower PROs but not with GC-specific domains, suggesting that ECOG-PS may not reflect GC-specific symptom burden at baseline 

@OncoAlert #GI26
jgong15's tweet image. Dr. Kato post-hoc analysis of RATIONALE-305 trial of #1L chemo +/- tisle in adv #GC/GEJC ➡️ higher baseline ECOG-PS sig associated w/lower PROs but not with GC-specific domains, suggesting that ECOG-PS may not reflect GC-specific symptom burden at baseline 

@OncoAlert #GI26
jgong15's tweet image. Dr. Kato post-hoc analysis of RATIONALE-305 trial of #1L chemo +/- tisle in adv #GC/GEJC ➡️ higher baseline ECOG-PS sig associated w/lower PROs but not with GC-specific domains, suggesting that ECOG-PS may not reflect GC-specific symptom burden at baseline 

@OncoAlert #GI26

T-minus one month before 1Ls hit orientation for law school. If you want 100 tips for success, we wrote this for you. Especially for first-gen students and those unfamiliar with what to expect. nyupress.org/9781479801626/… #books #1L #lawschool

ProfFerguson's tweet image. T-minus one month before 1Ls hit orientation for law school.  If you want 100 tips for success, we wrote this for you.  Especially for first-gen students and those unfamiliar with what to expect.  nyupress.org/9781479801626/… #books #1L #lawschool

Dr. Ko @UCSFCancer with an insightful discussant section on differences b/t #allele-specific #KRAS inhibitors vs. pan-RAS inhibitors & #1L landscape in metastatic #PDAC: RAS inh mono or in combo with chemo is the way to go? @ronanhsieh @OncoAlert #GI26

jgong15's tweet image. Dr. Ko @UCSFCancer with an insightful discussant section on differences b/t #allele-specific #KRAS inhibitors vs. pan-RAS inhibitors & #1L landscape in metastatic #PDAC: RAS inh mono or in combo with chemo is the way to go? @ronanhsieh 

@OncoAlert #GI26
jgong15's tweet image. Dr. Ko @UCSFCancer with an insightful discussant section on differences b/t #allele-specific #KRAS inhibitors vs. pan-RAS inhibitors & #1L landscape in metastatic #PDAC: RAS inh mono or in combo with chemo is the way to go? @ronanhsieh 

@OncoAlert #GI26

Dr. Peer KEYMAKER-U04 PhI/II substudy 04B of #1L EV + anti-LAG3 or anti-TIGIT coformulations w/pembro in #mUC ➡️ no clinically significant impact w/addition of LAG3 or TIGIT-targeted IO over EV-pembro alone, ORR 66% vs 59% vs 57%, PFS 11.3 vs 14.1 bs 11 mos @OncoAlert #GU26

jgong15's tweet image. Dr. Peer KEYMAKER-U04 PhI/II substudy 04B of #1L EV + anti-LAG3 or anti-TIGIT coformulations w/pembro in #mUC ➡️ no clinically significant impact w/addition of LAG3 or TIGIT-targeted IO over EV-pembro alone, ORR 66% vs 59% vs 57%, PFS 11.3 vs 14.1 bs 11 mos

@OncoAlert #GU26
jgong15's tweet image. Dr. Peer KEYMAKER-U04 PhI/II substudy 04B of #1L EV + anti-LAG3 or anti-TIGIT coformulations w/pembro in #mUC ➡️ no clinically significant impact w/addition of LAG3 or TIGIT-targeted IO over EV-pembro alone, ORR 66% vs 59% vs 57%, PFS 11.3 vs 14.1 bs 11 mos

@OncoAlert #GU26
jgong15's tweet image. Dr. Peer KEYMAKER-U04 PhI/II substudy 04B of #1L EV + anti-LAG3 or anti-TIGIT coformulations w/pembro in #mUC ➡️ no clinically significant impact w/addition of LAG3 or TIGIT-targeted IO over EV-pembro alone, ORR 66% vs 59% vs 57%, PFS 11.3 vs 14.1 bs 11 mos

@OncoAlert #GU26
jgong15's tweet image. Dr. Peer KEYMAKER-U04 PhI/II substudy 04B of #1L EV + anti-LAG3 or anti-TIGIT coformulations w/pembro in #mUC ➡️ no clinically significant impact w/addition of LAG3 or TIGIT-targeted IO over EV-pembro alone, ORR 66% vs 59% vs 57%, PFS 11.3 vs 14.1 bs 11 mos

@OncoAlert #GU26

@skopetz PhIII BREAKWATER Cohort 3 final analysis of #1L FOLFIRI +/- EC in #BRAFV600E MT #mCRC 64% vs 39.2%, trend in OS in favor of FOLFIRI + EC, 4% G5 AE vs 1.4% in control (note irino was 180 mg/m2), no diff in tx discontinuation @OncoAlert #GI26 @ronanhsieh

jgong15's tweet image. @skopetz PhIII BREAKWATER Cohort 3 final analysis of #1L FOLFIRI +/- EC in #BRAFV600E MT #mCRC 64% vs 39.2%, trend in OS in favor of FOLFIRI + EC, 4% G5 AE vs 1.4% in control (note irino was 180 mg/m2), no diff in tx discontinuation 

@OncoAlert #GI26 @ronanhsieh
jgong15's tweet image. @skopetz PhIII BREAKWATER Cohort 3 final analysis of #1L FOLFIRI +/- EC in #BRAFV600E MT #mCRC 64% vs 39.2%, trend in OS in favor of FOLFIRI + EC, 4% G5 AE vs 1.4% in control (note irino was 180 mg/m2), no diff in tx discontinuation 

@OncoAlert #GI26 @ronanhsieh
jgong15's tweet image. @skopetz PhIII BREAKWATER Cohort 3 final analysis of #1L FOLFIRI +/- EC in #BRAFV600E MT #mCRC 64% vs 39.2%, trend in OS in favor of FOLFIRI + EC, 4% G5 AE vs 1.4% in control (note irino was 180 mg/m2), no diff in tx discontinuation 

@OncoAlert #GI26 @ronanhsieh
jgong15's tweet image. @skopetz PhIII BREAKWATER Cohort 3 final analysis of #1L FOLFIRI +/- EC in #BRAFV600E MT #mCRC 64% vs 39.2%, trend in OS in favor of FOLFIRI + EC, 4% G5 AE vs 1.4% in control (note irino was 180 mg/m2), no diff in tx discontinuation 

@OncoAlert #GI26 @ronanhsieh

Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️

Quinthox's tweet image. Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️
Quinthox's tweet image. Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️

#STREAMLIGHT #PROTAC #1L-1AA 旧CREE XP-G2 新 Osram P9 H2T カスタム CREE XP-P 6500K Nichia 219C V2 5000K 90CRI LUMINUS SST-12 5000K ※非高演色 比較レビューです。 け、掲載は後ほど、、


Can a domain get much skinnier that 1l? Today, it's $2300 To prove a point, we'll offer it on March 1 for $1,111 (followers only) Does that make it a date worth remembering? 😄😍😃 #1L.work #memorable #short #domains

domainables's tweet image. Can a domain get much skinnier that 1l? 

Today, it's $2300
To prove a point, we'll offer it on March 1 for $1,111 (followers only)

Does that make it a date worth remembering? 😄😍😃
#1L.work #memorable #short #domains

Dr. Kamp rand PhII LyRICX trial in Netherlands pick-the-winner of #1L chemo backbones to #IO in HER2- adv #GEJC ➡️ capecitabine + carboplatin showed lower neurotoxicity with similar PFS to CAPOX w/favorable cost-effectiveness profile when added to #IO @OncoAlert #GI26

jgong15's tweet image. Dr. Kamp rand PhII LyRICX trial in Netherlands pick-the-winner of #1L chemo backbones to #IO in HER2- adv #GEJC ➡️ capecitabine + carboplatin showed lower neurotoxicity with similar PFS to CAPOX w/favorable cost-effectiveness profile when added to #IO

@OncoAlert #GI26
jgong15's tweet image. Dr. Kamp rand PhII LyRICX trial in Netherlands pick-the-winner of #1L chemo backbones to #IO in HER2- adv #GEJC ➡️ capecitabine + carboplatin showed lower neurotoxicity with similar PFS to CAPOX w/favorable cost-effectiveness profile when added to #IO

@OncoAlert #GI26
jgong15's tweet image. Dr. Kamp rand PhII LyRICX trial in Netherlands pick-the-winner of #1L chemo backbones to #IO in HER2- adv #GEJC ➡️ capecitabine + carboplatin showed lower neurotoxicity with similar PFS to CAPOX w/favorable cost-effectiveness profile when added to #IO

@OncoAlert #GI26
jgong15's tweet image. Dr. Kamp rand PhII LyRICX trial in Netherlands pick-the-winner of #1L chemo backbones to #IO in HER2- adv #GEJC ➡️ capecitabine + carboplatin showed lower neurotoxicity with similar PFS to CAPOX w/favorable cost-effectiveness profile when added to #IO

@OncoAlert #GI26

With the absence of @RealisticPurdue, I believe we have forgotten the mission all season, and I believe that is what to blame here. It’s time to restore and rebuild. #1L


Dr. Du China-based #RCT (RCT-PAAG) of #1L #GA+ penpulimab (PD-1 inh) & anlotinib (anti-angiogenic) ➡️ maint penpulimab/anlotinib (PAAG) or maint #GA (AG) ⬆️ ORR 49% vs 26% & mOS 13.9 vs 10.5 mos in favor of PAAG arm @OncoAlert #GI26

jgong15's tweet image. Dr. Du China-based #RCT (RCT-PAAG) of #1L #GA+ penpulimab (PD-1 inh) & anlotinib (anti-angiogenic) ➡️ maint penpulimab/anlotinib (PAAG) or maint #GA (AG) ⬆️ ORR 49% vs 26% & mOS 13.9 vs 10.5 mos in favor of PAAG arm

@OncoAlert #GI26
jgong15's tweet image. Dr. Du China-based #RCT (RCT-PAAG) of #1L #GA+ penpulimab (PD-1 inh) & anlotinib (anti-angiogenic) ➡️ maint penpulimab/anlotinib (PAAG) or maint #GA (AG) ⬆️ ORR 49% vs 26% & mOS 13.9 vs 10.5 mos in favor of PAAG arm

@OncoAlert #GI26
jgong15's tweet image. Dr. Du China-based #RCT (RCT-PAAG) of #1L #GA+ penpulimab (PD-1 inh) & anlotinib (anti-angiogenic) ➡️ maint penpulimab/anlotinib (PAAG) or maint #GA (AG) ⬆️ ORR 49% vs 26% & mOS 13.9 vs 10.5 mos in favor of PAAG arm

@OncoAlert #GI26
jgong15's tweet image. Dr. Du China-based #RCT (RCT-PAAG) of #1L #GA+ penpulimab (PD-1 inh) & anlotinib (anti-angiogenic) ➡️ maint penpulimab/anlotinib (PAAG) or maint #GA (AG) ⬆️ ORR 49% vs 26% & mOS 13.9 vs 10.5 mos in favor of PAAG arm

@OncoAlert #GI26

#Streamlight #HL-X #1L-1AA 両方ともXP-Pの3000k 拡散系もいいけどスポット系を好みます。 低ケルビンも好みです😁

Morino_Iyashi's tweet image. #Streamlight
#HL-X
#1L-1AA
両方ともXP-Pの3000k
拡散系もいいけどスポット系を好みます。
低ケルビンも好みです😁

Dr. Mahalingam @LurieCancer rand PhII of #1L #GA +/- elraglusib (GSK-3beta inh) in untreated met #PDAC ➡️ significant OS benefit (median 10.1 vs 7.2 mos, HR 0.62) in favor of novel combo over #GA alone. ORR 28.4 vs 21.8%. Transient visual impairment common AE @OncoAlert #GI26

jgong15's tweet image. Dr. Mahalingam @LurieCancer rand PhII of #1L #GA +/- elraglusib (GSK-3beta inh) in untreated met #PDAC ➡️ significant OS benefit (median 10.1 vs 7.2 mos, HR 0.62) in favor of novel combo over #GA alone. ORR 28.4 vs 21.8%. Transient visual impairment common AE

@OncoAlert #GI26
jgong15's tweet image. Dr. Mahalingam @LurieCancer rand PhII of #1L #GA +/- elraglusib (GSK-3beta inh) in untreated met #PDAC ➡️ significant OS benefit (median 10.1 vs 7.2 mos, HR 0.62) in favor of novel combo over #GA alone. ORR 28.4 vs 21.8%. Transient visual impairment common AE

@OncoAlert #GI26
jgong15's tweet image. Dr. Mahalingam @LurieCancer rand PhII of #1L #GA +/- elraglusib (GSK-3beta inh) in untreated met #PDAC ➡️ significant OS benefit (median 10.1 vs 7.2 mos, HR 0.62) in favor of novel combo over #GA alone. ORR 28.4 vs 21.8%. Transient visual impairment common AE

@OncoAlert #GI26
jgong15's tweet image. Dr. Mahalingam @LurieCancer rand PhII of #1L #GA +/- elraglusib (GSK-3beta inh) in untreated met #PDAC ➡️ significant OS benefit (median 10.1 vs 7.2 mos, HR 0.62) in favor of novel combo over #GA alone. ORR 28.4 vs 21.8%. Transient visual impairment common AE

@OncoAlert #GI26

Dr. Huang @sjtu1896 single-arm PhII trial of #1L fruquintinib + serplulimab (anti-PD1) in adv #nccRCC ➡️ median PFS NR, 9-mo PFS rate 87.3%, ORR 52.8%, AE profile consistent with respective agent safety profiles @OncoAlert #GU26

jgong15's tweet image. Dr. Huang @sjtu1896 single-arm PhII trial of #1L fruquintinib + serplulimab (anti-PD1) in adv #nccRCC ➡️ median PFS NR, 9-mo PFS rate 87.3%, ORR 52.8%, AE profile consistent with respective agent safety profiles 

@OncoAlert #GU26
jgong15's tweet image. Dr. Huang @sjtu1896 single-arm PhII trial of #1L fruquintinib + serplulimab (anti-PD1) in adv #nccRCC ➡️ median PFS NR, 9-mo PFS rate 87.3%, ORR 52.8%, AE profile consistent with respective agent safety profiles 

@OncoAlert #GU26
jgong15's tweet image. Dr. Huang @sjtu1896 single-arm PhII trial of #1L fruquintinib + serplulimab (anti-PD1) in adv #nccRCC ➡️ median PFS NR, 9-mo PFS rate 87.3%, ORR 52.8%, AE profile consistent with respective agent safety profiles 

@OncoAlert #GU26
jgong15's tweet image. Dr. Huang @sjtu1896 single-arm PhII trial of #1L fruquintinib + serplulimab (anti-PD1) in adv #nccRCC ➡️ median PFS NR, 9-mo PFS rate 87.3%, ORR 52.8%, AE profile consistent with respective agent safety profiles 

@OncoAlert #GU26

Me getting called on my #1l year

Piers Morgan asked Russell Brand which passages were relevant to him when he brought a Bible into court.



Me getting called on in my first year of law school #1l


bhai meeko kli btao jab bhi mai long krta hu bc ulta he kyu jata hai ? #NiftyIT #1L loss running @InvestorOfJAMMU any chances of recovery in IT specialy in tcs?


If you can’t explain a case out loud, you don’t understand it. That’s why cold calls feel brutal for most 1Ls. #LawSchool #1L #LawStudent #LegalAce


Barrister’s Ball ‘26 #1L

espinoza_abcde's tweet image. Barrister’s Ball ‘26 #1L
espinoza_abcde's tweet image. Barrister’s Ball ‘26 #1L
espinoza_abcde's tweet image. Barrister’s Ball ‘26 #1L

we going up this year #1L


we doin ts off da muscle , no co sign #1L


God help me achieve my dream. #1l


Btw, pizza dog is the now the biggest reason that has made you my #1l favorite artist Pizza dog is so cute and some other words :3


#Streamlight #HL-X #1L-1AA 両方ともXP-Pの3000k 拡散系もいいけどスポット系を好みます。 低ケルビンも好みです😁

Morino_Iyashi's tweet image. #Streamlight
#HL-X
#1L-1AA
両方ともXP-Pの3000k
拡散系もいいけどスポット系を好みます。
低ケルビンも好みです😁

Ofertas do Dia | Garrafa Térmica 1L Roxa com Isolamento a Vácuo Link amzn.to/3NQ3cQK Por apenas: R$ 56,90 Cartão Mercado Pago mpago.li/1hQYCzT GRUPOS E REDES SOCIAIS bio.site/ofertas.dehoje #garrafatermica #1l #acoinox #isolamentoavácuo #garrafatérmica #bbb

ofertasdehoje_'s tweet image. Ofertas do Dia | Garrafa Térmica 1L Roxa com Isolamento a Vácuo

Link amzn.to/3NQ3cQK

Por apenas: R$ 56,90 

Cartão Mercado Pago
mpago.li/1hQYCzT

GRUPOS E REDES SOCIAIS
bio.site/ofertas.dehoje

#garrafatermica #1l #acoinox #isolamentoavácuo #garrafatérmica #bbb

Rather be where they gone remember me .. im the reason 🛩️ #1L


@oneliquid_ $1L oneliquid makes it real — seamless swaps, unified pools & next-gen DeFi power. The era of fragmented liquidity is over 💧 #DeFi #Crypto #1L Oneliquid revolutionizes DeFi with seamless cross-chain liquidity. The $1L token empowers community governance and


Oneliquid isn’t building hype — it’s building the infrastructure for how DeFi should really work: Private. Fast. Rewarding. The $1L token ties it all together. I’m bullish — this is what next-gen trading looks like. 🌊 #Oneliquid #DeFi #1L


🚀 Big things are coming with @oneliquid_! The future of DeFi is here with seamless swaps, liquidity solutions & an upcoming token sale you don’t want to miss. 🔥 Be early. Be ready. $1L is the key. 🪙 #DeFi #Crypto #1L @oneliquid_ $1L


#1L are Rocking their socks for Down Syndrome Awareness Day today! #WDSAD #downsyndromeawareness #RockYourSocks

StMaryB17's tweet image. #1L are Rocking their socks for Down Syndrome Awareness Day today! #WDSAD #downsyndromeawareness #RockYourSocks
StMaryB17's tweet image. #1L are Rocking their socks for Down Syndrome Awareness Day today! #WDSAD #downsyndromeawareness #RockYourSocks

#広告の品 #キッコーマン #1ℓ 年末年始にはより使う頻度も多いお醤油 お得なこの広告の品 お買い忘れのないようにしてください🛒💁🏻‍♀️ ※広告の品 12月8日(金)迄となります。 #お一人様一本限り #しょうゆ

229summit's tweet image. #広告の品
#キッコーマン
#1ℓ

年末年始にはより使う頻度も多いお醤油
お得なこの広告の品 お買い忘れのないようにしてください🛒💁🏻‍♀️

※広告の品 12月8日(金)迄となります。
#お一人様一本限り
#しょうゆ
229summit's tweet image. #広告の品
#キッコーマン
#1ℓ

年末年始にはより使う頻度も多いお醤油
お得なこの広告の品 お買い忘れのないようにしてください🛒💁🏻‍♀️

※広告の品 12月8日(金)迄となります。
#お一人様一本限り
#しょうゆ

横綱ジョッキしか勝たん!笑 メガハイボールとの差!笑 #横綱 #1ℓ #ビール

nojima_masaya's tweet image. 横綱ジョッキしか勝たん!笑

メガハイボールとの差!笑

#横綱
#1ℓ
#ビール

Remember times was hard we prayed for better days💫 #1L

1lDeon's tweet image. Remember times was hard we prayed for better days💫 #1L
1lDeon's tweet image. Remember times was hard we prayed for better days💫 #1L
1lDeon's tweet image. Remember times was hard we prayed for better days💫 #1L
1lDeon's tweet image. Remember times was hard we prayed for better days💫 #1L

Started my day by reading a thank you note from a #1L contracts student from last term. #contracts isn’t always fun but I’m so glad when they notice that I try to make it so!

Kish_Parella's tweet image. Started my day by reading a thank you note from a #1L contracts student from last term. 

#contracts isn’t always fun but I’m so glad when they notice that I try to make it so!

Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️

Quinthox's tweet image. Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️
Quinthox's tweet image. Black lawyers make up 5% of lawyers in the legal profession. For me, this journey is personal. #1L ⚖️

てんしばでオクフェスやってるやん。しかも最終日。並びが少なそうだから1杯だけ飲も。ヴァルシュタイナー美味すぎやねん。 #1L

884kou's tweet image. てんしばでオクフェスやってるやん。しかも最終日。並びが少なそうだから1杯だけ飲も。ヴァルシュタイナー美味すぎやねん。
#1L

Had fun working out together with this @uidaholaw #1L Leah! #lawschool

DawnKYoung's tweet image. Had fun working out together with this @uidaholaw #1L Leah! #lawschool

Curious about working in #biglaw? Join us in our #Chicago office for an informational seminar for #1L students to learn more about working at a large law firm. Partners and associates will discuss their experiences at a large firm, including how they chose their areas of

Holland_Knight's tweet image. Curious about working in #biglaw? Join us in our #Chicago office for an informational seminar for #1L students to learn more about working at a large law firm. Partners and associates will discuss their experiences at a large firm, including how they chose their areas of

T-minus one month before 1Ls hit orientation for law school. If you want 100 tips for success, we wrote this for you. Especially for first-gen students and those unfamiliar with what to expect. nyupress.org/9781479801626/… #books #1L #lawschool

ProfFerguson's tweet image. T-minus one month before 1Ls hit orientation for law school.  If you want 100 tips for success, we wrote this for you.  Especially for first-gen students and those unfamiliar with what to expect.  nyupress.org/9781479801626/… #books #1L #lawschool

#1L and #2L summer associates: register for @ColumbusBar 2023 Summer Associates Program to learn from #LegalTech thought leader @IvyBGrey from WordRake. She’ll present “Improving Legal Judgment for Research and Writing” on 6/2, 10:25-11am ET. hubs.li/Q01R6xJl0

WordRake's tweet image. #1L and #2L summer associates: register for @ColumbusBar 2023 Summer Associates Program to learn from #LegalTech thought leader @IvyBGrey from WordRake. She’ll present “Improving Legal Judgment for Research and Writing” on 6/2, 10:25-11am ET. hubs.li/Q01R6xJl0

#1L are enjoying celebrating the end of the Jubilee year with @BhamDES. As the year draws to a close, the children are reflecting on how they have been pilgrims of hope and have lived out the beatitudes throughout the year. #Jubilee

StMaryB17's tweet image. #1L are enjoying celebrating the end of the Jubilee year with @BhamDES. As the year draws to a close, the children are reflecting on how they have been pilgrims of hope and have lived out the beatitudes throughout the year. #Jubilee

Good morning, still backing the boilers. #1L

RealisticPurdue's tweet image. Good morning, still backing the boilers. #1L
RealisticPurdue's tweet image. Good morning, still backing the boilers. #1L
RealisticPurdue's tweet image. Good morning, still backing the boilers. #1L
RealisticPurdue's tweet image. Good morning, still backing the boilers. #1L

One more sleep until the game tomorrow. Gonna listen to some Sensational, good night all #1L

RealisticPurdue's tweet image. One more sleep until the game tomorrow. 

Gonna listen to some Sensational, good night all #1L

Trusting ourselves is a nice way to get out of our comfort zones. ⁦@LeanderISD#1L.I.S.D.

gg_glover's tweet image. Trusting ourselves is a nice way to get out of our comfort zones. ⁦@LeanderISD⁩ #1L.I.S.D.

Attention J.D. Class of 2027! Please join H&K for a reception for #1L students in our #Tampa or #Jacksonville office during your winter break. Celebrate the New Year and the completion of your first semester of #lawschool while enjoying food, drinks and getting to know our

Holland_Knight's tweet image. Attention J.D. Class of 2027! Please join H&K for a reception for #1L students in our #Tampa or #Jacksonville office during your winter break. Celebrate the New Year and the completion of your first semester of #lawschool while enjoying food, drinks and getting to know our

🚨#postASH_ES ➡️ Tras conocer lo más relevante del tratamiento en #1L, @paurotero, de @ClinicaNavarra, presenta las novedades en el tratamiento de #rescate en #MielomaMultiple . 🗣️”Cada vez vamos a ver más pacientes triples expuestos y los esquemas de tratamiento pueden quedarse

sehh_es's tweet image. 🚨#postASH_ES ➡️ Tras conocer lo más relevante del tratamiento en #1L, @paurotero, de @ClinicaNavarra, presenta las novedades en el tratamiento de #rescate en #MielomaMultiple .
🗣️”Cada vez vamos a ver más pacientes triples expuestos y los esquemas de tratamiento pueden quedarse
sehh_es's tweet image. 🚨#postASH_ES ➡️ Tras conocer lo más relevante del tratamiento en #1L, @paurotero, de @ClinicaNavarra, presenta las novedades en el tratamiento de #rescate en #MielomaMultiple .
🗣️”Cada vez vamos a ver más pacientes triples expuestos y los esquemas de tratamiento pueden quedarse
sehh_es's tweet image. 🚨#postASH_ES ➡️ Tras conocer lo más relevante del tratamiento en #1L, @paurotero, de @ClinicaNavarra, presenta las novedades en el tratamiento de #rescate en #MielomaMultiple .
🗣️”Cada vez vamos a ver más pacientes triples expuestos y los esquemas de tratamiento pueden quedarse
sehh_es's tweet image. 🚨#postASH_ES ➡️ Tras conocer lo más relevante del tratamiento en #1L, @paurotero, de @ClinicaNavarra, presenta las novedades en el tratamiento de #rescate en #MielomaMultiple .
🗣️”Cada vez vamos a ver más pacientes triples expuestos y los esquemas de tratamiento pueden quedarse

Loading...

Something went wrong.


Something went wrong.